- Home
- ED vs VCEL Comparison
ED vs VCEL Comparison
Compare ED & VCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ED
- VCEL
- Stock Information
- Founded
- ED 1884
- VCEL 1989
- Country
- ED United States
- VCEL United States
- Employees
- ED 14592
- VCEL N/A
- Industry
- ED Power Generation
- VCEL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ED Utilities
- VCEL Health Care
- Exchange
- ED Nasdaq
- VCEL Nasdaq
- Market Cap
- ED 31.0B
- VCEL 2.8B
- IPO Year
- ED N/A
- VCEL 1997
- Fundamental
- Price
- ED $89.41
- VCEL $58.67
- Analyst Decision
- ED Hold
- VCEL Strong Buy
- Analyst Count
- ED 12
- VCEL 6
- Target Price
- ED $98.17
- VCEL $61.83
- AVG Volume (30 Days)
- ED 2.1M
- VCEL 365.5K
- Earning Date
- ED 02-13-2025
- VCEL 02-27-2025
- Dividend Yield
- ED 3.72%
- VCEL N/A
- EPS Growth
- ED N/A
- VCEL N/A
- EPS
- ED 5.31
- VCEL 0.07
- Revenue
- ED $15,031,000,000.00
- VCEL $226,844,000.00
- Revenue This Year
- ED $7.23
- VCEL $23.82
- Revenue Next Year
- ED $3.78
- VCEL $22.51
- P/E Ratio
- ED $16.83
- VCEL $800.63
- Revenue Growth
- ED N/A
- VCEL 22.48
- 52 Week Low
- ED $85.85
- VCEL $37.35
- 52 Week High
- ED $107.75
- VCEL $61.49
- Technical
- Relative Strength Index (RSI)
- ED 39.64
- VCEL 58.69
- Support Level
- ED $87.28
- VCEL $57.28
- Resistance Level
- ED $89.11
- VCEL $60.13
- Average True Range (ATR)
- ED 1.18
- VCEL 2.18
- MACD
- ED 0.31
- VCEL 0.14
- Stochastic Oscillator
- ED 74.74
- VCEL 65.34
About ED Consolidated Edison Inc.
Con Ed is a holding company for Consolidated Edison of New York, or CECONY, and Orange & Rockland, or O&R. These utilities provide steam, natural gas, and electricity to customers in southeastern New York—including New York City—and small parts of New Jersey. The two utilities generate nearly all of Con Ed's earnings following the sale of its clean energy business to RWE in early 2023.
About VCEL Vericel Corporation
Vericel Corp is a fully integrated, commercial-stage biopharmaceutical company, specialized in various therapies for sports medicine and severe burn care markets. It markets two cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane) and Epicel (cultured epidermal autografts). The company operates in one reportable segment: the research, product development, manufacture, and distribution of patient-specific, expanded cellular therapies for use in the treatment of specific diseases.